3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
3
Terminated
1
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Dexamethasone
20
daratumumab
17
Bortezomib
12
Lenalidomide
11
pomalidomide
8
Cyclophosphamide
8
Calcium Dobesilate
7
belantamab mafodotin
5
isatuximab
4
fludarabine
4
carfilzomib
4
Melphalan
4
dexamethasone acetate
3
dexamethasone 21-phosphate
3
auricularum
3
Specimen Handling
3
Biopsy
3
tocilizumab
2
iberdomide
2
Stem Cell Transplantation
2
Maintenance
2
Injections
2
Immunotherapy, Adoptive
2
Hyaluronoglucosaminidase
2
Fluorodeoxyglucose F18
2
Exercise Therapy
2
Drug Therapy
2
CT103A chimeric antigen receptor
2
zanubrutinib
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
dabrafenib
×
Plasma cell
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled